EMD Serono lays out MS therapies' immune-system suppression risks in new campaign
EMD Serono is leaning on drug differentiation in a new digital and social media campaign for Mavenclad, its multiple sclerosis treatment.
The “B Cells and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
